InterOcean Capital Group LLC Buys 569 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

InterOcean Capital Group LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,663 shares of the biopharmaceutical company’s stock after buying an additional 569 shares during the quarter. InterOcean Capital Group LLC’s holdings in Gilead Sciences were worth $702,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its stake in Gilead Sciences by 6.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 3,295 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 211 shares during the last quarter. Journey Strategic Wealth LLC bought a new stake in Gilead Sciences during the 4th quarter worth approximately $202,000. Western Pacific Wealth Management LP raised its position in Gilead Sciences by 53.5% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,022 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 356 shares during the last quarter. Quest Partners LLC acquired a new position in Gilead Sciences in the fourth quarter worth $1,529,000. Finally, STF Management LP grew its holdings in shares of Gilead Sciences by 3.4% during the fourth quarter. STF Management LP now owns 21,074 shares of the biopharmaceutical company’s stock worth $1,707,000 after purchasing an additional 686 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on GILD shares. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Barclays dropped their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. Wells Fargo & Company lowered their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Finally, TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $83.69.

Gilead Sciences Stock Down 0.9 %

Shares of GILD stock traded down $0.60 during trading hours on Thursday, hitting $67.20. 878,653 shares of the company were exchanged, compared to its average volume of 7,203,471. The company has a market capitalization of $83.72 billion, a PE ratio of 188.33, a PEG ratio of 1.35 and a beta of 0.22. The business has a 50 day moving average of $68.77 and a two-hundred day moving average of $74.70. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.37 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.58%. Gilead Sciences’s payout ratio is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.